ArticleFrontiers in cellular and infection microbiology2025
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Formononetin: a promising therapeutic agent targeting the gut-lung axis in acute lung injury.Frontiers in pharmacology · 2026Article
- Factors influencing gut microbial colonization: A host-microbe-environment interaction perspective.Current research in food science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bile acids (BAs) are central to host-microbiota interactions, yet their metabolism in wild rodents remains poorly characterized. This study aimed to explore the genomic potential of gut microorganisms in wild rodents for BA metabolism and its implications for host adaptation and pathogen interactions. Methods: We reconstructed 6,332 genomes from the gut microbiota of wild rodents and performed genome-resolved metabolic profiling. Comparative analyses were conducted across host species, including humans, pigs, laboratory mice, and chickens. Functional enrichment was further assessed in relation to glycoside hydrolase families and Enterocytozoon bieneusi infection status. Results: A total of 5,208 genomes were identified as participants in key BA metabolic pathways, including deconjugation, oxidation, and dihydroxylation, predominantly from Bacillota_A and Bacteroidota. Notably, Muribaculaceae and CAG-485 lineages within Bacteroidota encoded bile salt hydrolase (BSH). Cross-species comparisons revealed a striking absence of 7β-hydroxysteroid dehydrogenase (7β-HSDH) in laboratory mice, indicating their limited suitability for modeling intestinal BA metabolism. BSH-encoding genomes were significantly enriched in glycoside hydrolase families GH13 and GH16, suggesting a potential link between BA transformation and carbohydrate metabolism. Furthermore, Enterocytozoon bieneusi infection was associated with a marked increase in BA-related microbial taxa in wild rodents. Discussion: Our findings highlight the intricate interconnections between gut microbial functions, BA metabolism, and pathogen interactions. The absence of 7β-HSDH in laboratory mice underscores wild rodents as potentially more suitable models for BA research. These results open new avenues for understanding microbiome-driven host adaptation and health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.